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Background: The role of neutrophil gelatinase-associated lipocalin (NGAL) as a diagnostic marker for acute kidney
injury (AKI) in sepsis is still debated. We hypothesized that in sepsis, the performance of serum(s) and urinary(u)
NGAL can be negatively impacted by severity of illness and inflammation, and that both uNGAL and sNGAL levels
can be increased regardless of presence of AKI.
Methods: One hundred and seven patients with sepsis were included. uNGAL and sNGAL were measured at
admission (T0) and 4 hours (T4) and 24 hours later (T24). Transient and intrinsic AKI were respectively defined as AKI
according to RIFLE during the first 72 hours that did or did not recover to “no AKI” in the following 72 hours.
Patients were classified according to tertiles of CRP and APACHE II score increase. The relationship between sNGAL
and uNGAL was assessed by linear regression.
Results: Fifty-seven patients developed transient and 22 intrinsic AKI. Prevalence of transient and intrinsic AKI were
higher in patients with versus without septic shock (OR (95% CI):3.3(1.4-8.2)). uNGAL was associated with sNGAL, and this
with parallel slopes but different intercepts for AKI (Y = 0.87*X + 314.3,R2 = 0.31) and no AKI (Y = 0.87*X + 20.1,R2 = 0.38). At
T4, median uNGAL and sNGAL levels were higher in septic patients with versus without shock but this is independent of
AKI ((545 ng/mL vs 196 ng/ml for uNGAL and 474 ng/ml vs 287 ng/ml for sNGAL (both P = 0.003)). Both uNGAL
and sNGAL levels increased with tertiles of CRP and APACHE II score increase.
Conclusions: Serum and uNGAL levels are influenced by severity of illness and inflammation, and this was found to
be independent of the presence of AKI. There is a strong correlation between sNGAL and uNGAL levels in patients
with sepsis, indicating that increased levels of uNGAL can also be due to overspill from the systemic circulation,
blurring the discriminative value of NGAL as a biomarker for AKI in patients with sepsis.
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Septic acute kidney injury (AKI) is associated with worse
outcome compared to non-septic AKI and is regarded as
a distinct clinical entity [1]. The unacceptably high mor-
tality rates associated with septic AKI are partly explained
by an incomplete understanding of the pathophysiology
and a delay in diagnosis [2-6]. Early diagnosis of septic
or non-septic AKI remains cumbersome because it re-
lies on imperfect parameters such as serum creatinine
while introduction of new serum and urinary bio-
markers could hypothetically allow earlier diagnosis and
better prognostication [7-9]. At present, NGAL (neutro-
phil gelatinase-associated lipocalin) has been the most
frequently investigated biomarker for early diagnosis of
AKI [10]. In humans, three different forms of NGAL
can be found, namely a 25 kDa monomer, a 45 kDa
dimer and a 135 kDa heterodimer, covalently conjugated
with gelatinase [11-13]. Up till now, no commercially
available immunoassays are able to make a clear dis-
crimination between the monomer, mainly released
from tubular epithelial cells, and the dimer, originating
from neutrophils [12].
Some studies found increased urinary NGAL levels in
patients classified as having transient AKI, suggesting
presence of subtle tubular structural injury [14,15]. In
addition, studies where there was a rise in biomarker
level (either in serum or urine) without a rise in serum
creatinine or a decrease in urinary output, resulted in
speculation on the existence of a new entity called sub-
clinical AKI [16,17]. However, serum NGAL levels can
be increased in many other conditions beside acute kidney
injury, such as inflammation [18]. As serum NGAL is
filtered at the glomerular level, also urinary NGAL can
potentially be influenced by inflammation [19-21].
The present study aims to characterize the origin of
the raised serum and urine levels of NGAL in septic pa-
tients. We hypothesized that, as in sepsis patients, the
prevalence of AKI is related to severity of sepsis, which
in turn is associated with an increase in urinary and
serum NGAL levels, a correlation between both urinary
and serum NGAL, and severity of illness could exist, in-
dependent of the presence of AKI.
Methods
Study cohort
One hundred and seven consecutive patients with sepsis,
admitted to the Ghent University Hospital between
12/01/2010 and 05/09/2010, were prospectively enrolled.
Sepsis, severe sepsis or septic shock were defined accord-
ing to the American College of Chest Physicians/Society
of Critical Care Medicine Consensus Conference guide-
lines [22]. Briefly, sepsis was defined when two or
more of the following conditions were present as a
result of infection: 1) temperature >38° or < 36°, 2)heart rate >90 beats/min, 3) respiratory rate >20
breaths/min or PaCO2 < 32 mmHg (<4,3 kPa) or 4)
white blood cell count >12000 cells/mm3 or <4000 cells/
mm3, or >10% immature (band) forms. Severe sepsis was
defined as sepsis associated with organ dysfunction, hypo-
perfusion or hypotension. Sepsis with shock was defined
as sepsis with hypotension despite adequate fluid resusci-
tation or vasopressor need. Since only four patients were
not classified as having either severe sepsis or septic
shock, we combined sepsis and severe sepsis in a new cu-
mulative category ‘sepsis without shock’, as opposed to
‘sepsis with shock’. Exclusion criteria were 1) a history of
liver and/or kidney transplantation, 2) ICU stay less than
24 hours, 3) patients treated with chronic haemodialysis
and 4) age <17 years.
Fluid management and decision-making for need of
RRT were done by intensivists, who were blinded to the
study, and according to protocols applied in the study
hospital. The study was approved by the ethical commit-
tee of the Ghent University Hospital. Written informed
consent was obtained from the patient or their next of
kin. Research adhered to the tenets of the Declaration of
Helsinki.
Study definitions
We defined AKI based on the worst of either serum cre-
atinine or urinary output criteria according to RIFLE
[23]. The urinary output criterion was based on 6-hour
blocks, as described by Macedo et al. [24]. Baseline
serum creatinine was based on the most recent value be-
fore admission or was estimated with the MDRD equa-
tion if the latter was not available [23].
Transient acute kidney injury was defined as presence
of AKI according to RIFLE, occurring in the first three
days after admission and returning to no AKI within the
following 72 hours. Intrinsic AKI was defined as pres-
ence of AKI according to RIFLE in the first three days of
admission that did not improve to no AKI in the follow-
ing 72 hours. Patients who left ICU before 5 days after
admission were followed up at the department they were
transferred to.
Sample collection
Urine and blood samples were collected at the moment
of admission (T0), four hours later (T4) and 24 hours
later (T24). Blood samples were centrifuged at 1500 g for
10 minutes within 20 minutes after collection, and serum
was aliquoted and stored at −80°C for later batch analysis.
Urine was collected in a sterile manner and centrifuged at
500 g for 10 minutes, and urine samples were aliquoted
and stored at −80°C for later batch analysis.
Serum and urinary neutrophil gelatinase-associated
lipocalin (NGAL) were measured using an ELISA kit
(BioportoR Diagnostics Denmark).
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After informed consent, demographics and medical his-
tory were obtained. Laboratory and clinical data were
registered in a dedicated database. APACHE II scores
were calculated over the first 24 hours of admission.
Patients were classified according to tertiles of serum
C-reactive protein (CRP) levels (CRP ≤20.10 mg/dL,
CRP 20.11-30.70 mg/dL and CRP ≥30.71 mg/dL) and
APACHE II score increase (APACHE II <20, APACHE II
20–25 and APACHE II >25).
Statistical analysis
Results are reported as medians and interquartile ranges
(IQR) for continuous variables, unless otherwise speci-
fied. Discrete variables are reported as numbers and/or
percentages. All statistical analyses were performed
using SPSS® 19. All consecutive patients fulfilling the in-
clusion criteria were included, irrespective of their
course or duration of stay at ICU.
Demographic characteristics of the study cohort were
compared using using Mann–Whitney U test (two
groups) or Kruskal Wallis (>two groups) (continuous
variables not normally distributed). Student’s t test (two
groups) or one-way ANOVA (>two groups) were used toTable 1 Clinical and demographic characteristics of the cohor
no A
Gender male (%) 51.7
Age (years,mean/sd) 55.4(1
Reason for admission (%):
Respiratory 46.4
Abdominal 21.4
Urinary 7.1
Endocarditis 3.6
Neurological 7.1
Catheter 10.7
Other 3.6
CKD on admission (eGFR according to MDRD <60 mL/min/1,73 m2) (%) 10.7
APACHE II score on the first day of admission 21(10
Fluid balance first 24 hours (liter, mean/sd) 2.2(1.8
Use of diuretics on the first day of admission (%) 7.1
RRT need during ICU stay (%) 0
Vasopressor use (%) 32.1
Total dose of noradrenaline first 24 h in μg/kg/min (mean/sd) 0.05(0
Maximum dose of noradrenaline during first 24 h
in μg/kg/min (mean/sd)
0.12(0
Need for ventilation during ICU stay (%) 39.3
LOS in the ICU (days) 5(6)
ICU mortality (%) 21.4
Mortality at 90 days (%) 28.6compare means (continuous variables with normal
distribution).
As planned, patients were classified according to sepsis
status (sepsis without vs sepsis with shock), AKI status
(no AKI vs transient AKI vs intrinsic AKI) and tertiles of
CRP and APACHE II score for comparison.
Dichotomous variables were compared between
groups using Chi square analysis.
Regression analysis was used to assess association be-
tween serum and urinary NGAL.Results
Demographics and clinical background of the 107 in-
cluded patients are presented in Tables 1 and 2 as par-
tially published elsewhere [25] (Tables 1 and 2). Sepsis
without shock was present in 42 (39.3%) patients and
sepsis with shock in 65 (60.7%) patients. Twenty-eight
(26.2%) patients were classified as having no AKI versus
57 (53.3%) and 22 (20.6%) as having transient and intrin-
sic AKI, respectively. Median APACHE II score was 21
in sepsis patients without shock and 23 in those with
shock (P = 0.22) and increased from no AKI over transi-
ent AKI to intrinsic AKI (P = 0.08).t comparing no-AKI vs transient AKI vs intrinsic AKI
KI (n = 28) Transient AKI (n = 57) Intrinsic AKI (n = 22) p value
54.4 59.1 0.93
7.3) 62.6(13.2) 63.1(14.9) 0.08
0.11
38.6 36.4
33.3 36.4
8.8 0
7.0 0
0 4.5
1.8 0
10.5 22.7
8.8 9.1 1
) 22(8) 24.5(9) 0.08
) 3.1(1.9) 5.4(2.7) <0.001
14 22.7 0.29
1.8 59.1 <0.001
61.4 86.4 <0.001
.11) 0.09(0.12) 0.20(0.22) 0.001
.23) 0.25(0.31) 0.54(0.55) 0.008
50.9 86.4 0.002
5(10) 38(32) 0.014
15.8 54.2 0.002
24.6 59.1 0.012
Table 2 Clinical and demographic characteristics of the cohort comparing sepsis patients without vs with shock
Sepsis without shock (n = 42) Sepsis with shock (n = 65) p value
Gender male (%) 50 60 0.31
Age (years,mean/sd) 57.6(15.6) 62.9(14.3) 0.16
Reason for admission (%): 0.02
Respiratory 47.6 35.4
Abdominal 14.3 41.5
Urinary 14.3 1.5
Endocarditis 2.4 6.2
Neurological 4.8 1.5
Catheter 4.8 3.1
Other 11.9 10.8
CKD on admission (MDRD <60 mL/min/1,73 m2) (%) 16.7 4.6 0.04
APACHE II score on the first day of admission 21(9) 23(9) 0.22
AKI (transient or intrinsic) (%) 25(59.5) 54(83.1) 0.007
Fluid balance first 24 hours (liter, mean/sd) 2.06(2.21) 3.8(2.58) <0.001
Use of diuretics on the first day of admission (%) 9.5 16.9 0.28
RRT need during ICU stay (%) 0 21.5 0.001
Total dose of noradrenaline first 24 h in μg/kg/min (mean/sd) N/A 0.17(0.16) N/A
Maximum dose of noradrenaline during first 24 h in μg/kg/min (mean/sd) N/A 0.44(0.41) N/A
Need for ventilation during ICU stay (%) 39.3 73.8 <0.001
LOS in the ICU (days) 4(6) 7(16) 0.03
ICU mortality (%) 14.3 32.3 0.04
Mortality at 90 days (%) 19.0 41.5 0.02
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had transient or intrinsic AKI (35/65 vs 22/42 and 19/65
vs 3/42, respectively, P = 0.007). There was also an in-
creasing positive fluid balance, need for ventilation,
length of ICU stay and mortality from no AKI over tran-
sient AKI to intrinsic AKI and in patients with versus
those without shock. Fourteen patients needed RRT
(Tables 1 and 2).
Median urinary and serum NGAL levels were higher in
sepsis patients with versus those without shock (Figure 1A,
B, C and Table 3). All no AKI patients had serum NGAL
levels above the generally accepted cut-off of 150 ng/mL
[26,27] at all time points. All sepsis patients with shock
had urinary NGAL levels above 150 ng/mL at admission
and four hours later, even if they did not have AKI. Urin-
ary and serum NGAL levels were higher in intrinsic versus
transient and no AKI patients, but there was substantial
overlap limiting discriminative value (Table 3). When clas-
sified according to sepsis without versus with shock, dis-
criminative value of NGAL for AKI further decreased
(Figure 2A, B and C).
Urinary and serum NGAL levels increased with tertiles
of CRP (175 ng/mL vs 229 ng/mL vs 563 ng/mL, for
uNGAL and 245 ng/mL vs 296 ng/mL vs 512 ng/mL forsNGAL (P = 0.006 and P = 0.04, respectively) (Figure 3A
and B). Neither uNGAL or sNGAL had a discriminative
value for differentiating AKI (transient or intrinsic) from
no AKI (Figure 3C and D).
We found a strong correlation between sNGAL and
uNGAL, both in patients without and with AKI (R2 = 0.38
for no AKI and R2 = 0.31 for AKI), but with different
relationships in no AKI (Y = 0.87*X + 20.1) versus AKI
(Y = 0.87*X + 314.3), respectively (P < 0.001). The
slopes of the regression lines followed a parallel course
(Figure 4).
Analyses of the correlation between sNGAL and uNGAL
levels at the other time points demonstrated comparable
findings (data not shown).
There was also a correlation between the APACHE II
score and uNGAL (P = 0.002, P <0.001 and P = 0.003 at
T0, T4 and T24) and between the APACHE II score and
sNGAL (P = 0.007, P = 0.003 and P = 0.07 at T0,T4 and
T24). Median urinary NGAL levels increased with in-
creasing tertiles of APACHE II (179 ng/mL vs 355 ng/
mL vs 405 ng/mL for APACHE II <20, 20–25 and >25
respectively, P = 0.04) (Figure 5). There was an increas-
ing trend in serum NGAL levels over the first two ter-
tiles (Figure 5).
Figure 1 Urinary and serum NGAL in sepsis without vs with shock. A: Urinary NGAL (ng/mL) at time point T0 is higher in sepsis with vs
without shock (P = 0.003). There is a trend for higher serum NGAL levels (ng/mL) in sepsis with vs without shock (P = 0.083). B: Serum and urinary
NGAL (ng/mL) at time point T4 are higher in sepsis with shock vs without shock (both P = 0.003). C: Serum NGAL (ng/mL) at time point T24 is
higher in sepsis with vs without shock (P = 0.011). There is a trend for higher urinary NGAL levels (ng/ml) in sepsis with vs without shock
(P = 0.082). (° = outliers; * = extreme outliers (> three times the height of the boxes)).
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Table 3 Urinary NGAL and serum NGAL (ng/mL) in no AKI vs transient and intrinsic AKI
Sepsis without shock Sepsis with shock
No AKI
(n = 17)
Transient
AKI (n = 22)
Intrinsic
AKI (n = 3)
p value No AKI
(n = 11)
Transient
AKI (n = 35)
Intrinsic
AKI (n = 19)
p value Overall
p value
uNGAL T0 125(262) 262(350) 1276 0.27* 178(457) 649(1164) 1775(2108) 0.08* 0.001#
uNGAL T4 116(256) 234(310) 1044 0.27* 269(511) 523(1384) 1802(2046) 0.03* 0.009#
uNGAL T24 122(218) 239(383) 1245 0.27* 137(612) 405(1523) 2372(2308) 0.11* 0.084#
sNGAL T0 220(269) 288(477) 235 0.44* 290(221) 493(579) 962(894) 0.003* 0.03#
sNGAL T4 218(193) 336(338) 284 0.17* 267(192) 469(604) 975(940) 0.011* 0.002#
sNGAL T24 203(189) 295(364) 184 0.44* 283(188) 475(435) 1052(670) 0.001* 0.001#
*P-values refer to the difference between no AKI, transient AKI and intrinsic AKI, separately for patients with vs without shock.
#P-values refer to the difference between no AKI, transient AKI and intrinsic AKI either with or without shock at each time point.
Figure 2 Urinary NGAL in no AKI, transient AKI and intrinsic AKI, stratified according to sepsis severity. (A) At time point T0, urinary
NGAL(ng/ml) is not significantly different between no-AKI, transient AKI and intrinsic AKI in sepsis without shock (P = 0.27) and sepsis with shock
(P = 0.08). (B) At time point T4, urinary NGAL(ng/ml) is not significantly different between no AKI, transient AKI and intrinsic AKI in sepsis without
shock (P = 0.27). (C) At time point T24, urinary NGAL (ng/mL) is not significantly different between no-AKI, transient AKI and intrinsic AKI in sepsis
without shock (P = 0.27) and sepsis with shock (P = 0.11). (° = outliers; * = extreme outliers (> three times the height of the boxes)).
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Figure 3 Influence of inflammation on serum and urinary NGAL. (A): Urinary NGAL (ng/mL) increases together with increasing levels of CRP.
(B): Serum NGAL (ng/mL) increases together with increasing levels of CRP. (C): Urinary NGAL (ng/mL) is not significantly different between AKI
(transient or intrinsic) and no AKI, when stratified according to tertiles of CRP increase. (D): Serum NGAL (ng/mL) is not significantly different
between AKI (transient or intrinsic) and no AKI in the two lower tertiles of CRP increase. (° = outliers; * = extreme outliers (> three times the height
of the boxes)).
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In this cohort of septic ICU patients, we confirmed that the
risk for AKI increased with severity of sepsis. Serum and
urinary levels of NGAL increased with severity of illness
and inflammation, as assessed by APACHE II and CRP. In
addition, there was a strong correlation between urinary
and serum levels of NGAL, irrespective of presence of AKI.
Although there was a significant difference in uNGAL
levels between no AKI, transient AKI and intrinsic AKI,
this difference did not remain when patients were stratified
according to severity of sepsis (sepsis with or without
shock) and to tertiles of CRP or APACHE II score increase,
except for sNGAL in the highest CRP tertile where a sig-
nificant difference between AKI and no AKI could be
found. However, across all tertiles, there was an important
overlap in NGAL levels between AKI and no AKI, theresult being that NGAL is not a reliable biomarker to dis-
criminate between AKI and no AKI in the individual case.
It remains unclear whether in sepsis patients, in-
creased urinary NGAL is a marker of structural tubular
injury, the result of overspill from the systemic circula-
tion or just a marker of severity of illness. This is also
emphasized by the fact that no commercially available
assays make a distinction between ‘renal’ NGAL and
‘neutrophil’ NGAL. Cai et al. confirmed that NGAL is
present in different forms in the urine by using five ELI-
SAs (using different monoclonal and polyclonal anti-
bodies) and one polyclonal-based RIA [11]. Authors
concluded that it should be possible to construct an
assay that preferentially identifies NGAL originating
from the tubular epithelium or the neutrophils. Martens-
son et al. demonstrated that the ratio of two ELISAs,
Figure 4 Linear regression between serum NGAL and urinary NGAL in no AKI and AKI. For no AKI: y = 0.87*x + 20.1 and for AKI: y = 0.87*x + 314.3.
R2 for AKI = 0.31 and R2 for no-AKI = 0.38 (P <0.001).
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the monomeric form (which mainly originates from
renal tubular cells) with an AUC ROC of 0.92 in ICU
patients without CKD [13]. However, more recently,
Glassford et al. assessed monomeric and dimeric uNGAL
contribution using western blotting-validated enzyme-
linked immunosorbent assays and their calculated ratio in
102 patients with SIRS and found that at best, urinary
forms of NGAL are fair predictors of renal or patients out-
come. The authors conclude that the nature and source of
uNGAL are complex and challenge the utility of NGAL as
a uniform biomarker [12].
NGAL is filtered into the primary urine and almost
completely reabsorbed by the tubular epithelium via the
megalin receptor under normal circumstances [28]. One
of the concerns of using NGAL as a biomarker for AKI
is that even in the absence of AKI, NGAL levels can in-
crease during inflammation [18,29-33]. We demon-
strated that in patients with sepsis, serum NGAL levels
increase in parallel with the severity of sepsis, severity of
illness and severity of inflammation and thus increased
levels might not automatically reflect tubular damage.
High levels of serum NGAL can overwhelm the reab-
sorbing capacity of the proximal tubule so that urinary
NGAL levels might increase, even in the absence of
structural tubular injury. We found a strong correlation
between serum and urinary NGAL levels, both in pa-
tients without and with AKI. The value of urinary NGALfor differentiating between AKI and no AKI was also low
due to overlap between the two groups, irrespective of
severity of illness, sepsis or inflammation.
These findings underline that the concept of “subclin-
ical AKI” should be used with caution, however, they do
not contradict the existence of this concept in certain
patients. Indeed, urinary NGAL was well correlated with
serum NGAL (R2 = 0.37), but the regression line went
through the origin for no AKI patients, whereas it did
not in AKI patients. This suggests that in AKI, there is
some degree of either local tubular production or re-
duced reabsorption, both of which may reflect tubular
injury.
In any case, our data indicate that the suggestion to
use uNGAL as a diagnostic marker because of its al-
legedly discriminating role in differentiating AKI from
no AKI should be carefully considered, at least in pa-
tients with sepsis. In addition, when including patients
with ‘subclinical AKI’, based on NGAL positivity only, in
an interventional trial, those interventions that only
focus on preventing or healing tubular injury risk to be
less useful. The latter because, in a substantial part of
patients, the increased urinary NGAL will not be the re-
sult of tubular damage but rather of overspill from the
circulation as a consequence of high circulating levels
induced by inflammation.
Designing an immunoassay that perfectly discriminates
between monomer and dimer NGAL will only partly solve
Figure 5 Influence of severity of illness on serum and urinary NGAL. (A): Urinary NGAL (ng/mL) increases together with tertiles of APACHE II
score increase. (B): There is a trend for increasing serum NGAL (ng/mL) together with APACHE II score increase, in the two lower tertiles. (C):
Urinary NGAL (ng/mL) is not significantly different between AKI (transient or intrinsic) and no AKI, in the two lower tertiles of APACHE II score
increase. (D) Serum NGAL(ng/ml) is not significantly different between AKI (transient or intrinsic) and no AKI, when stratified according to tertiles
of APACHE II score increase. (° = outliers; * = extreme outliers (> three times the height of the boxes)).
Vanmassenhove et al. BMC Nephrology  (2015) 16:18 Page 9 of 10this issue. Since the common pathway in CKD relates to
tubulointerstitial damage which in turn could imply high
levels of monomer NGAL, a tool that allows the measure-
ment of monomer NGAL only, would not be helpful in
differentiating between AKI, acute on chronic kidney dis-
ease and CKD. Also, the role of leukocytes in the patho-
physiology of septic AKI is being increasingly recognized
[34]. So the presence of dimer NGAL can also be an indi-
cation of local tubular damage rather than just being a
sign of glomerular overflow or presence of leukocyturia in
the context of urinary infection.
A limitation of this observational study is that it de-
scribes a relatively small cohort of septic patients. How-
ever, to our knowledge, this is the first study providing
information on prospectively collected serum and urin-
ary NGAL levels at different time points during the first
24 hours after admission in septic patients.Conclusions
In patients with sepsis, levels of urinary and serum
NGAL and the prevalence and severity of AKI are
strongly associated with severity of illness and inflamma-
tion as expressed by APACHE II and CRP. There is a
strong correlation in sepsis patients between serum and
urinary levels of NGAL, irrespective of presence of AKI.
Therefore, the conclusion that presence of NGAL in the
urine implies tubular injury should be made very cau-
tiously in sepsis patients.
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